Calculates AREDS2 5-year AMD progression risk based on drusen size, pigment changes, and pseudodrusen, and determines AREDS2 supplement eligibility (antioxidants + zinc, lutein, zeaxanthin, omega-3).
BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).
BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.
Calculates AREDS2 5-year AMD progression risk based on drusen size, pigment changes, and pseudodrusen, and determines AREDS2 supplement eligibility (antioxidants + zinc, lutein, zeaxanthin, omega-3)
Each component has a specific meaning:
Note: Interpret the amd risk score result against the clinical thresholds and context described above.
Enter the drusen size, pigment changes, pseudodrusen, determines AREDS2 supplement eligibility (antioxidants + zinc, lutein, zeaxanthin for the patient or scenario you are assessing. Calculates AREDS2 5-year AMD progression risk based on drusen size, pigment changes, and pseudodrusen, and determines AREDS2 supplement eligibility (antioxidants + zinc, lutein, zeaxanthin, omega-3). Use the amd risk score result to inform your clinical assessment.